Biotech Values

[gofishmarko]

>> The absence of the intended immune response in the Provenge group suggests that, if anything, the placebo group has a chance to benefit from the procedure rather than being disadvantaged. <<

This is something I'm not quite clear on. Is the placebo infusion treated identically to Provenge , except for the addition of fusion antigen , or is it simply stored and reinfused ?

The APC-enrichment steps that are done prior to antigen incubation could be the MOA of Provenge , for all they know , so if the placebo prep does not get this treatment that is indeed a serious flaw in the trial design.

Anybody know , offhand ?